Skip to content
Dosage GuideResearch Reference

LL-37 Dosage

Research-based dosing protocols, timing guidance, and reconstitution reference for LL-37. All information is for educational purposes only.

Quick Answer

Due to the preclinical stage of LL-37 research, there are no standardized human dosages. Animal studies have used a wide range of concentrations depending on the application (antimicrobial, wound healing, etc.). Formulations range from topical creams to subcutaneous injections, with concentrations varying accordingly. Any human use would be experimental and off-label.

→ LL-37 Benefits→ LL-37 Side Effects→ Full LL-37 Profile
Table of Contents

Standard Dosage Range

Research dosing range: No standardized human dosage exists

Educational reference only

These dosage ranges are derived from preclinical research and community protocols. No human clinical dose-ranging trials have established therapeutic doses for most research peptides. Always consult a qualified healthcare provider before starting any peptide protocol.

Dosage by Use Case

Wound Healing (Topical)

Concentrations vary widely (e.g., 0.1-1% in creams/ointments)1-2× daily
Duration

Until healing is observed (typically several weeks)

Topical application directly to the wound site. Formulations aim to deliver LL-37 locally to stimulate keratinocyte migration and angiogenesis. No established clinical efficacy data.

Antimicrobial (Topical/Injection - Experimental)

Varied concentrations (e.g., 10-100 mcg/mL for topical; 1-10 mcg/kg for injection in animal models)Variable, depending on infection severity
Duration

Until infection clears or for a specified treatment course

Concentration and route of administration would depend on the type and location of the infection. Systemic administration (injection) carries greater risk and should only be considered in severe, refractory cases under strict medical supervision. No clinical trials support safety or efficacy.

Immune Modulation (Subcutaneous - Experimental)

Dosages extrapolated from animal models vary widely (e.g., 1-5 mcg/kg)1× daily or every other day
Duration

Limited by safety and tolerability concerns

Administered subcutaneously. Intended to influence cytokine production and innate immune cell function. Risk of immune over-activation or autoimmune reactions exists. No human studies exist.

Timing & Frequency

Timing depends on the route of administration and intended use. Topical applications are generally applied after cleansing the affected area. In preclinical models using injections, administration has been performed at various times of day, with no specific timing showing superior outcomes.

Cycle Guidance

Given the absence of human data, cycle guidance is speculative. If used experimentally, short cycles (e.g., 4-6 weeks) followed by a break of equal length may be considered to mitigate potential long-term risks. Continuous use is not recommended due to lack of safety information.

Reconstitution Reference

Quick reference for reconstituting LL-37. For custom vial sizes and concentrations, use the Reconstitution Calculator.

Common Vial SizeTypically supplied in varying amounts, e.g., 1 mg, 5 mg per vial
BAC Water VolumeDependent on desired concentration, e.g., 1 mL bacteriostatic water for 1 mg/mL concentration
Concentration & DrawVaries depending on reconstitution. Example: At 1 mg/mL: 10 mcg = 0.01 mL (1 unit on a 100-unit insulin syringe)
StorageRefrigerate at 2–8°C after reconstitution. Keep lyophilized powder at -20°C (freezer) for long-term storage.
StabilityReconstituted solution stable for a limited time (e.g., 7-14 days) refrigerated. Lyophilized powder stable for several months to years, depending on manufacturer specifications and storage temperature.
Use the Reconstitution Calculator → for precise injection volumes based on your exact vial size, water volume, and desired dose.

Frequently Asked Questions

What is the proper LL-37 dosage for wound healing?
There is no established dosage for human wound healing. Topical application of creams containing LL-37 at varying concentrations (0.1-1%) has been explored in preclinical studies. Consult with a medical professional before considering any off-label use.
Can LL-37 be taken orally?
Oral bioavailability of LL-37 is likely limited due to enzymatic degradation in the digestive tract. Other routes of administration, such as topical application or injection, are more common in preclinical studies. No oral formulations are currently available, and the effectiveness of oral LL-37 is unproven.
How is LL-37 typically administered?
In research settings, LL-37 has been administered topically, subcutaneously, intravenously, and via inhalation (depending on the model). The optimal route of administration depends on the specific application and target tissue. Human use would be experimental and under medical supervision.

Last updated: 2026-02-19